-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Sanofi and IGM Biosciences announced a research and development collaboration to develop agonists against three oncology targets and three immunology/inflammation targets using IGM Biosciences' unique IgM antibody technology platform
.
The press release states that the collaboration aims to develop a new potential therapeutic modality that exploits the multivalent nature of IgM to create agonists that better activate cell surface receptors
To develop a new potential therapeutic modality that exploits the multivalent nature of IgM to create agonists that better activate cell surface receptors
IgM is a type of antibody produced in the body, and unlike normal IgG antibodies, they have 10 sites where they can bind to antigens, a feature that increases their affinity for their targets
.
The high affinity of IgM antibodies allows them to bind strongly to targets that are difficult to bind or are poorly expressed on the cell surface, and they have the ability to simultaneously bind to multiple targets on the cell surface
The high affinity of IgM antibodies allows them to bind strongly to targets that are difficult to bind or are poorly expressed on the cell surface, and they have the ability to simultaneously bind to multiple targets on the cell surface
▲The different structures of IgM and IgG antibodies (Image source: IGM Biosciences official website)
▲The different structures of IgM and IgG antibodies (Image source: IGM Biosciences official website) Under the partnership agreement, IGM will receive an upfront payment of $150 million
.
For the oncology collaboration, IGM will lead R&D activities until regulatory approval by the US FDA or EU EMA
In terms of immunology/inflammation collaboration, IGM will be responsible for R&D activities until the completion of Phase 1 clinical trials, and Sanofi will be responsible for subsequent development
.
For each target, IGM is eligible to receive up to $1.
Dr.
John Reed, global head of R&D at Sanofi, said: "We look forward to working with IGM Biosciences, whose technology platform provides the ability to develop high-affinity IgM antibodies that bind efficiently to cell surface receptors and activate their activity
.
The unique platform has the potential to overcome the historical limitations of traditional IgG antibodies
This unique platform has the potential to overcome the historical limitations of traditional IgG antibodies
Original source: https://
https://
